Cost-effectiveness of therapeutic drug monitoring: A systematic review

Therapeutic Drug Monitoring

Volumn 27, Issue 1, 2005, Pages 10-17

  Touw, D J ^a   Neef, C ^b   Thomson, A H ^c   Vinks, A A ^d  

^a Apotheek Haagse Ziekenhuizen   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c WESTERN INFIRMARY   (United Kingdom)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Cost benefit analysis; Cost effectiveness analysis; TDM

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTICONVULSIVE AGENT; CAFFEINE; CARBAMAZEPINE; CYCLOSPORIN; DESIPRAMINE; DIGOXIN; FELBAMATE; GABAPENTIN; IMIPRAMINE; IMMUNOSUPPRESSIVE AGENT; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; NORTRIPTYLINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROTEINASE INHIBITOR; RAPAMYCIN; TACROLIMUS; THEOPHYLLINE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VANCOMYCIN; VIGABATRIN; ZONISAMIDE;

APNEA; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; EPILEPSY; GRAFT REJECTION; HEALTH CARE; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW;

COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG MONITORING; DRUG UTILIZATION REVIEW; HUMANS;

EID: 13244271254     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200502000-00004     Document Type: Review

References (48)

1. Watson I, Potter J, Yatscoff R, et al. Editorial. Therapeutic drug monitoring. Ther Drug Monit. 1997;19:125.
2. Donabedian A. Evaluating the quality of medical care. Milbank Q. 1966;44:166-206.
3. Schumacher GE, Barr JT. Economic and outcome issues for therapeutic drug monitoring in medicine. Ther Drug Monit. 1998;20:539-542.
4. st century. Clin Pharmacokinet. 1998;34:265-279.
5. Vinks AATMM, Eerland JJ, Harteveld AR, et al. Analysis and dosing of antibiotics in a renal patient: continuing education through EQUAS. Ther Drug Monit. 1995;17:415.
6. Bootman JL, Wertheimer AI, Zaske D, et al. Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost-benefit analysis. J Pharm Sci. 1979;68:267-272.
7. Destache CJ, Meyer SK, Padomek MT, et al. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides for gram-negative infections. DICP. 1989;23:33-38.
8. Destache CJ, Meyer SK, Bittner MJ, et al. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: A cost-benefit analysis. Ther Drug Monit. 1990;12:419-426.
9. Destache CJ, Meyer SK, Rowley KM. Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis. Ther Drug Monit. 1990;12:427-433.
10. Van Lent-Evers NAEM, Mathot RAA, Geus WP, et al. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: A cost-effectiveness analysis. Ther Drug Monit. 1999;21:63-73.
11. Streetman DS, Nafziger AN, Destache CJ, et al. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy. 2001;21:443-451.
12. Vinks AA. Pharmacokinetic monitoring of aminoglycosides in the extended dosing interval era. J Lab Med. 2002;26:43-48.
13. Darko W, Medicis JJ, Smith A, et al. Mississippi mud no more: Cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy. 2003;23:643-650.
14. Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother. 1994;28:1335-1339.
15. Del Mar Fernández de Gatta M, Calvo V, Hernández JM, et al. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther. 1996;60:332-340.
16. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteraemia. Pharmacotherapy. 1995;15:85-91.
17. Mulhern JG, Braden GL, O'Shea MH, et al. Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. Am J Kidney Dis. 1995;25:611-615.
18. Jannuzzi G, Cian P, Fattore C, et al. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy. Epilepsia. 2000;41:222-230.
19. Schoenenberger RA, Tanasijevic MJ, Jha A, et al. Appropriateness of antiepileptic drug level monitoring. JAMA. 1995;274:1622-1626.
20. Bates DW, Soldin SJ, Rainey PM, et al. Strategies for physician education in therapeutic drug monitoring. Clin Chem. 1998;44:401-407.
21. Warner A, Privitera M, Bates D. Standards of laboratory practice: antiepileptic drug monitoring. Clin Chem. 1998;44:1085-1095.
22. Eadie MJ. The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy. Clin Pharmacokinet. 1995;29:29-35.
23. Rane CT, Dalvi SS, Gogtay NJ, et al. A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic-clonic epilepsy. Br J Clin Pharmacol. 2001;52:193-195.
24. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003;25:347-363.
25. Burton ME, Vasko MR, Brater DC. Comparison of drug dosing methods. Clin Pharmacokinet. 1985;10:1-37.
26. Holford N, Black P, Couch R, et al. Theophylline target concentration in severe airways obstruction - 10 or 20 mg/L? A randomised concentration- controlled trial. Clin Pharmacokinet. 1993;25:495-505.
27. Kearns GL, Fischer TJ, Hunter RH. Use of serum theophylline determinations during acute asthma therapy in children. Ann Allergy. 1982;48:71-74.
28. Keijer WJ, Van Weissenbruch MM, Van Loenen AC, et al. Op weg naar verfijning van de dosering. Farmacokinetiek van coffeine bij neonaten met apneu. Pharm Weekbl. 2002;137:1021-1027.
29. Canas F, Tanasijevic MJ, Máluf N, et al. Evaluating the appropriateness of digoxin level monitoring. Arch Intern Med. 1999;159:363-368.
30. Kramer WG, Kolibash AJ, Lewis RP, et al. Pharmacokinetics of digoxin: relationship between response intensity and predicted compartmental drug levels in man. J Pharmacokinet Biopharm. 1979;7:47-61.
31. Riaz K, Forker AD. Digoxin use in congestive heart failure. Drugs. 1998;55:747-758.
32. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
33. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003; 289:871-878.
34. Johnston A, Holt DW. Immunosuppressant drugs - the role of therapeutic drug monitoring. Br J Clin Pharmacol. 2001;52:61S-73S.
35. Shaw L, Kaplan B, Brayman L. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem. 1998;44:381-387.
36. Holt DW, Armstrong VW, Griesmacher A, et al. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group on Immunosuppressive Drug Monitoring. Ther Drug Monit. 2002;24:59-67.
37. Cremers SCLM, Scholten EM, Schoemaker RC, et al. A compartmental pharmacokinetic model of cyclosporine and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients. Nephrol Dial Transplant. 2003;18(6):1201-1208.
38. Schou M, Juel-Nielsen N, Stromgren E, et al. The treatment of manic psychosis by the administration of lithium salts. J Neurol Neurosurg Psychiatry. 1954;17:250-260.
39. Amdisen A. Serum concentration and clinical supervision in monitoring of lithium treatment. Ther Drug Monit. 1980;2:73-83.
40. Mitchell PB. Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol. 2001;52(suppl):45-54.
41. Ulrich S, Baumann B, Wolf R, et al. Therapeutic drug monitoring of clozapine and relapse - a retrospective study of routine clinical data. Int J Clin Pharmacol Ther. 2003;41:3-13.
42. Gaertner I, Gaertner HJ, Vonthein R, et al. Therapeutic drug monitoring of clozapine in relapse prevention: A five-year prospective study. J Clin Psychiatry. 2001;21:305-310.
43. Grub S, Delora P, Ludin E, et al. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2002;71:122-130.
44. Casado JL, Moreno S, Hertogs K, et al. NELSANE study. Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen. AIDS. 2002;16:47-52.
45. Back DJ, Khoo SH, Gibbons SE, et al. The role of therapeutic drug monitoring in treatment of HIV infection. Br J Clin Pharmacol. 2001;52:89S-96S.
46. Burger DM, Hugen PWH, Aernoutse RE, et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit. 2003;25:73-80.
47. Hugen PWH, Burger DM, Aarnoutse RE, et al. Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance. Ther Drug Monit. 2002;24:579-587.
48. Hugen PWH, Langebeek N, Burger DM, et al. Assessment of adherence to HIV protease inhibitors: Comparison and combinations of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J AIDS. 2002;30:324-334.